CoChat
Sign Up
Cited by 663Advanced Drug Delivery SystemsDrug Solubulity and Delivery SystemsNanoparticle-Based Drug Delivery

Adapting liposomes for oral drug delivery

Open access
He, Haisheng, Lu, Yi, Qi, Jianping, Zhu, Quangang, Chen, Zhongjian, Wu, Wei·2019·Acta Pharmaceutica Sinica B
DOI 10.1016/j.apsb.2018.06.005PMC PMC6362257
Open this paper in CoChat — free accountOpen PDF

Abstract

Liposomes mimic natural cell membranes and have long been investigated as drug carriers due to excellent entrapment capacity, biocompatibility and safety. Despite the success of parenteral liposomes, oral delivery of liposomes is impeded by various barriers such as instability in the gastrointestinal tract, difficulties in crossing biomembranes, and mass production problems. By modulating the compositions of the lipid bilayers and adding polymers or ligands, both the stability and permeability of liposomes can be greatly improved for oral drug delivery. This review provides an overview of the challenges and current approaches toward the oral delivery of liposomes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.apsb.2018.06.005

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Liposomes offer better biocompatibility and safety than polymeric and metal-based nanoparticles due to their resemblance to biomembranes.

    “Indeed, they offer better biocompatibility and safety than polymeric and metal-based nanoparticles due to their resemblance to biomembranes [204,205].”

    From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [204]

    The Introduction says liposomes’ biocompatibility and safety are advantages arising from their resemblance to biomembranes. It does not establish that they are better on those measures than polymeric or metal-based nanoparticles; searches for that comparison found no supporting passage. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 168

  1. [1]Bangham A.D. Horne R.W. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope J Mol Biol 8 1964 660 668 14187392
  2. [3]Gregoriadis G. Swain C. Wills E. Tavill A. Drug-carrier potential of liposomes in cancer chemotherapy Lancet 303 1974 1313 1316 4134296
  3. [4]Gregoriadis G. Florence A.T. Liposomes in drug delivery Clin, Diagn Ophthalmic Potential Drugs 45 1993 15 28 7680982
  4. [5]Gregoriadis G. Fate of injected liposomes: observations on entrapped solute retention, vesicle clearance and tissue distribution in vitro Gregoriadis G. Liposomes as drug carriers: recent trends and progress 1988 Plenum Press New York 3 18
  5. [6]Moghimi S.M. Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties Prog Lipid Res 42 2003 463 478 14559067
  6. [7]Yan X. Scherphof G.L. Kamps J.A. Liposome opsonization J Liposome Res 15 2005 109 139 16194930
  7. [8]Palchetti S. Colapicchioni V. Digiacomo L. Caracciolo G. Pozzi D. Capriotti A.L. The protein corona of circulating PEGylated liposomes Biochim Biophys Acta 1858 2016 189 196 26607013
  8. [9]Tang J. Kuai R. Yuan W. Drake L. Moon J.J. Schwendeman A. Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting Nanomedicine 13 2017 1869 1878 28434931 PMC5554706
  9. [10]Pereira S. Egbu R. Jannati G. Al-Jamal W.T. Docetaxel-loaded liposomes: the effect of lipid composition and purification on drug encapsulation and in vitro toxicity Int J Pharm 514 2016 150 159 27863659
  10. [11]Huang X. Li M. Bruni R. Messa P. Cellesi F. The effect of thermosensitive liposomal formulations on loading and release of high molecular weight biomolecules Int J Pharm 524 2017 279 289 28377318
  11. [12]Signorell R.D. Papachristodoulou A. Xiao J. Arpagaus B. Casalini T. Grandjean J. Preparation of PEGylated liposomes incorporating lipophilic lomeguatrib derivatives for the sensitization of chemo-resistant gliomas Int J Pharm 536 2017 388 396 29198811
  12. [13]Bunker A. Magarkar A. Viitala T. Rational design of liposomal drug delivery systems, a review: combined experimental and computational studies of lipid membranes, liposomes and their PEGylation Biochim Biophys Acta 1858 2016 2334 2352 26915693
  13. [14]Suk J.S. Xu Q. Kim N. Hanes J. Ensign L.M. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery Adv Drug Deliv Rev 99 2016 28 51 26456916 PMC4798869
  14. [15]Liu J.X. Xin B. Li C. Xie N.H. Gong W.L. Huang Z.L. PEGylated perylenemonoimide-dithienylethene for super-resolution imaging of liposomes ACS Appl Mater Interfaces 9 2017 10338 10343 28281748
  15. [16]Griffin J.I. Wang G. Smith W.J. Vu V.P. Scheinman R. Stitch D. Revealing dynamics of accumulation of systemically injected liposomes in the skin by intravital microscopy ACS Nano 11 2017 11584 11593 29045127 PMC5770233
  16. [18]Weissig V. Liposomes came first: the early history of liposomology Methods Mol Biol 1522 2017 1 15 27837526
  17. [19]Xing H. Hwang K. Lu Y. Recent developments of liposomes as nanocarriers for theranostic applications Theranostics 6 2016 1336 1352 27375783 PMC4924503
  18. [20]Daraee H. Etemadi A. Kouhi M. Alimirzalu S. Akbarzadeh A. Application of liposomes in medicine and drug delivery Artif Cells Nanomed Biotechnol 44 2016 381 391 25222036
  19. [21]Noble G.T. Stefanick J.F. Ashley J.D. Kiziltepe T. Bilgicer B. Ligand-targeted liposome design: challenges and fundamental considerations Trends Biotechnol 32 2014 32 45 24210498
  20. [22]Caritá A.C. Eloy J.O. Chorilli M. Lee R.J. Leonardi G.R. Recent advances and perspectives in liposomes for cutaneous drug delivery Curr Med Chem 25 2018 606 635 28990515
  21. [23]Agrawal M. Ajazuddin Tripathi D.K. Saraf S. Saraf S. Antimisiaris S.G. Recent advancements in liposomes targeting strategies to cross blood–brain barrier (BBB) for the treatment of Alzheimer׳s disease J Control Release 260 2017 61 77 28549949
  22. [24]Kapoor M. Lee S.L. Tyner K.M. Liposomal drug product development and quality: current US experience and perspective AAPS J 19 2017 632 641 28160164
  23. [25]Patel H. Ryman B.E. Oral administration of insulin by encapsulation within liposomes FEBS Lett 62 1976 60 63 129340
  24. [26]Hashimoto A. Kawada J. Effects of oral administration of positively charged insulin liposomes on alloxan diabetic rats: preliminary study Endocrinol Jpn 26 1979 337 344 477621
  25. [27]Dapergolas G. Gregoriadis G. Hypoglycaemic effect of liposome-entrapped insulin administered intragastrically into rats Lancet 308 1976 824 827 61498
  26. [28]He H. Lu Y. Qi J. Zhao W. Dong X. Wu W. Biomimetic thiamine- and niacin-decorated liposomes for enhanced oral delivery of insulin Acta Pharm Sin B 8 2018 97 105 29872626 PMC5985626
  27. [29]Arrieta-Molero J. Aleck K. Sinha M. Brownscheidle C. Shapiro L. Sperling M. Orally administered liposome-entrapped insulin in diabetic animals Horm Res 16 1982 249 256 6751980
  28. [32]Tang W.L. Tang W.H. Chen W.C. Diako C. Ross C.F. Li S.D. Development of a rapidly dissolvable oral pediatric formulation for mefloquine using liposomes Mol Pharm 14 2017 1969 1979 28460165
  29. [33]Song Z. Lin Y. Zhang X. Feng C. Lu Y. Gao Y. Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects Int J Nanomed 12 2017 1941 1958 PMC5354530 28331317
  30. [34]Liu Y. Luo X. Xu X. Gao N. Liu X. Preparation, characterization and in vivo pharmacokinetic study of PVP-modified oleanolic acid liposomes Int J Pharm 517 2017 1 7 27899320
  31. [35]Verma A.K. Sharma S. Gupta P. Singodia D. Kansal S. Sharma V. Vitamin B12 grafted layer-by-layer liposomes bearing HBsAg facilitate oral immunization: effect of modulated biomechanical properties Mol Pharm 13 2016 2531 2542 27215337
  32. [36]Chen W.L. Yuan Z.Q. Liu Y. Yang S.D. Zhang C.G. Li J.Z. Liposomes coated with N-trimethyl chitosan to improve the absorption of harmine in vivo and in vitro Int J Nanomed 11 2016 325 336 PMC4725628 26855571
  33. [37]Uhl P. Helm F. Hofhaus G. Brings S. Kaufman C. Leotta K. A liposomal formulation for the oral application of the investigational hepatitis B drug Myrcludex B Eur J Pharm Biopharm 103 2016 159 166 27049970
  34. [38]Jensen S.M. Christensen C.J. Petersen J.M. Treusch A.H. Brandl M. Liposomes containing lipids from Sulfolobus islandicus withstand intestinal bile salts: an approach for oral drug delivery? Int J Pharm 493 2015 63 69 26192627
  35. [39]Chen H. Wu J. Sun M. Guo C. Yu A. Cao F. N-trimethyl chitosan chloride-coated liposomes for the oral delivery of curcumin J Liposome Res 22 2012 100 109 22007962
  36. [40]Wu W. Lu Y. Qi J. Oraldelivery ofliposomes Ther Deliv 6 2015 1239 1241 26584253
  37. [41]Thirawong N. Thongborisute J. Takeuchi H. Sriamornsak P. Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin–liposome nanocomplexes J Control Release 125 2008 236 245 18082282
  38. [42]Takeuchi H. Matsui Y. Yamamoto H. Kawashima Y. Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats J Control Release 86 2003 235 242 12526820
  39. [43]Iwanaga K. Ono S. Narioka K. Kakemi M. Morimoto K. Yamashita S. Application of surface-coated liposomes for oral delivery of peptide: effects of coating the liposome׳s surface on the GI transit of insulin J Pharm Sci 88 1999 248 252 9950646
  40. [44]Conacher M. Alexander J. Brewer J.M. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes) Vaccine 19 2001 2965 2974 11282208
  41. [45]Shukla A. Khatri K. Gupta P.N. Goyal A.K. Mehta A. Vyas S.P. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes) J Pharm Pharm Sci 11 2008 59 66 18445364
  42. [46]Choudhari K. Labhasetwar V. Dorle A. Liposomes as a carrier for oral administration of insulin: effect of formulation factors J Microencapsul 11 1994 319 325 8064555
  43. [47]Niu M. Lu Y. Hovgaard L. Guan P. Tan Y. Lian R. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose Eur J Pharm Biopharm 81 2012 265 272 22369880
  44. [48]Bozzuto G. Molinari A. Liposomes as nanomedical devices Int J Nanomed 10 2015 975 999 PMC4324542 25678787
  45. [49]Yamano E. Miyauchi M. Furusyo H. Kawazoe A. Ishikado A. Makino T. Inhibitory effects of orally administrated liposomal bovine lactoferrin on the LPS-induced osteoclastogenesis Lab Invest 90 2010 1236 1246 20421871
  46. [50]Hosny K.M. Ahmed O.A. Al-Abdali R.T. Enteric-coated alendronate sodium nanoliposomes: a novel formula to overcome barriers for the treatment of osteoporosis Exp Opin Drug Deliv 10 2013 741 746 23656470
  47. [51]Yang Z. Lu A. Wong B.C. Chen X. Bian Z. Zhao Z. Effect of liposomes on the absorption of water-soluble active pharmaceutical ingredients via oral administration Curr Pharm Des 19 2013 6647 6654 23621538
  48. [52]Hu S. Niu M. Hu F. Lu Y. Qi J. Yin Z. Integrity and stability of oral liposomes containing bile salts studied in simulated and ex vivo gastrointestinal media Int J Pharm 441 2013 693 700 23089580
  49. [53]Liu W. Ye A. Liu W. Liu C. Han J. Singh H. Behaviour of liposomes loaded with bovine serum albumin during in vitro digestion Food Chem 175 2015 16 24 25577045
  50. [54]Tian J.N. Ge B.Q. Shen Y.F. He Y.X. Chen Z.X. Thermodynamics and structural evolution during a reversible vesicle-micelle transition of a vitamin-derived bolaamphiphile induced by sodium cholate J Agric Food Chem 64 2016 1977 1988 26860930
  51. [55]Kokkona M. Kallinteri P. Fatouros D. Antimisiaris S.G. Stability of SUV liposomes in the presence of cholate salts and pancreatic lipases: effect of lipid composition Eur J Pharm Sci 9 2000 245 252 10594380
  52. [56]Cohn J.S. Kamili A. Wat E. Chung R.W. Tandy S. Dietary phospholipids and intestinal cholesterol absorption Nutrients 2 2010 116 127 22254012 PMC3257636
  53. [57]Shukla A. Mishra V. Kesharwani P. Bilosomes in the context of oral immunization: development, challenges and opportunities Drug Discov Today 21 2016 888 899 27038539
  54. [58]Lopes M.A. Abrahim B.A. Cabral L.M. Rodrigues C.R. Seiça R.M. de Baptista Veiga F.J. Intestinal absorption of insulin nanoparticles: contribution of M cells Nanomedicine 10 2014 1139 1151 24632248
  55. [60]Ensign L.M. Cone R. Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers Adv Drug Deliv Rev 64 2012 557 570 22212900 PMC3322271
  56. [61]Guan P. Lu Y. Qi J. Niu M. Lian R. Wu W. Solidification of liposomes by freeze-drying: the importance of incorporating gelatin as interior support on enhanced physical stability Int J Pharm 478 2015 655 664 25510601
  57. [62]van den Hoven J.M. Metselaar J.M. Storm G. Beijnen J.H. Nuijen B. Cyclodextrin as membrane protectant inspray-dryingand freeze-drying of PEGylatedliposomes Int J Pharm 438 2012 209 216 22960501
  58. [64]Chen C. Han D. Cai C. Tang X. An overviewofliposome lyophilization and its future potential J Control Release 142 2010 299 311 19874861
  59. [65]Kannan V. Balabathula P. Thoma L.A. Wood G.C. Effect of sucrose as a lyoprotectant on the integrity of paclitaxel-loadedliposomesduring lyophilization J Liposome Res 25 2015 270 278 25534990
  60. [66]Ali M.E. Lamprecht A. Spray freeze drying as an alternative technique for lyophilization of polymeric and lipid-based nanoparticles Int J Pharm 516 2016 170 177 27845211
  61. [67]Richards M.H. Gardner C.R. Effects of bile salts on the structural integrity of liposomes Biochim Biophys Acta 543 1978 508 522 718987
  62. [68]Kato Y. Hosokawa T. Hayakawa E. Ito K. Influence of liposomes on tryptic digestion of insulin Biol Pharm Bull 16 1993 457 461 8364491
  63. [70]Parmentier J. Thewes B. Gropp F. Fricker G. Oral peptide delivery by tetraether lipid liposomes Int J Pharm 415 2011 150 157 21664955
  64. [71]Cui M. Wu W. Hovgaard L. Lu Y. Chen D. Qi J. Liposomes containing cholesterol analogues of botanical origin as drug delivery systems to enhance the oral absorption of insulin Int J Pharm 489 2015 277 284 25957702
  65. [72]Muramatsu K. Maitani Y. Nagai T. Dipalmitoylphosphatidylcholine liposomes with soybean-derived sterols and cholesterol as a carrier for the oral administration of insulin in rats Biol Pharm Bull 19 1996 1055 1058 8874815
  66. [73]Parmentier J. Becker M.M. Heintz U. Fricker G. Stability of liposomes containing bio-enhancers and tetraether lipids in simulated gastro-intestinal fluids Int J Pharm 405 2011 210 217 21145956
  67. [74]Birru W.A. Warren D.B. Ibrahim A. Williams H.D. Benameur H. Porter C.J. Digestion of phospholipids after secretion of bile into the duodenum changes the phase behavior of bile components Mol Pharm 11 2014 2825 2834 24987935
  68. [75]Andrieux K. Forte L. Lesieur S. Paternostre M. Ollivon M. Grabielle-Madelmont C. Solubilisation of dipalmitoylphosphatidylcholine bilayers by sodium taurocholate: a model to study the stability of liposomes in the gastrointestinal tract and their mechanism of interaction with a model bile salt Eur J Pharm Biopharm 71 2009 346 355 18835441
  69. [76]Arafat M. Kirchhoefer C. Mikov M. Sarfraz M. Löbenberg R. Nanosized liposomes containing bile salt: a vesicular nanocarrier for enhancing oral bioavailability of BCS class III drug J Pharm Pharm Sci 20 2017 305 318 28885915
  70. [77]Aburahma M.H. Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide/protein-based therapeutics or vaccines Drug Deliv 23 2016 1847 1867 25390191
  71. [78]Guan P. Lu Y. Qi J. Niu M. Lian R. Hu F. Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt Int J Nanomed 6 2011 965 974 PMC3124400 21720508
  72. [79]Song K.H. Chung S.J. Shim C.K. Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts J Control Release 106 2005 298 308 15979756
  73. [80]Ayogu I. Ogbonna O. Ayolugbe C. Attama A. Evaluation of the pharmacodynamic activity of insulin from bilosomal formulation Curr Drug Deliv 6 2009 415 418 19534705
  74. [81]Niu M. Lu Y. Hovgaard L. Wu W. Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation Int J Nanomed 6 2011 1155 1166 PMC3148843 21822379
  75. [82]Barea M. Jenkins M. Gaber M. Bridson R. Evaluation of liposomes coated with a pH responsive polymer Int J Pharm 402 2010 89 94 20888403
  76. [83]Barea M. Jenkins M. Lee Y. Johnson P. Bridson R. Encapsulation of liposomes within pH responsive microspheres for oral colonic drug delivery Int J Biomater 2012 2012 458712 22792110 PMC3391899
  77. [84]Sehgal S. Rogers J.A. Polymer-coated liposomes: improved liposome stability and release of cytosine arabinoside (Ara-C) J Microencapsul 12 1995 37 47 7730955
  78. [85]Venkatesan N. Vyas S. Polysaccharide coated liposomes for oral immunization—development and characterization Int J Pharm 203 2000 169 177 10967439
  79. [86]Lee C.M. Lee H.C. Lee K.Y. O-palmitoylcurdlan sulfate (OPCurS)-coated liposomes for oral drug delivery J Biosci Bioeng 100 2005 255 259 16243273
  80. [87]Carafa M. Marianecci C. Annibaldi V. Di Stefano A. Sozio P. Santucci E. Novel O-palmitoylscleroglucan-coated liposomes as drug carriers: development, characterization and interaction with leuprolide Int J Pharm 325 2006 155 162 16884870
  81. [89]Smistad G. Bøyum S. Alund S.J. Samuelsen A.B.C. Hiorth M. The potential of pectin as a stabilizer for liposomal drug delivery systems Carbohydr Polym 90 2012 1337 1344 22939349
  82. [90]Nguyen T.X. Huang L. Liu L. Abdalla A.M.E. Gauthier M. Yang G. Chitosan-coated nano-liposomes for the oral delivery of berberine hydrochloride J Mater Chem B 2 2014 7149 7159 32261793
  83. [91]Kowapradit J. Apirakaramwong A. Ngawhirunpat T. Rojanarata T. Sajomsang W. Opanasopit P. Methylated N-(4-N,N-dimethylaminobenzyl) chitosan coated liposomes for oral protein drug delivery Eur J Pharm Sci 47 2012 359 366 22771544
  84. [92]Manconi M. Nacher A. Merino V. Merino-Sanjuan M. Manca M.L. Mura C. Improving oral bioavailability and pharmacokinetics of liposomal metformin by glycerolphosphate-chitosan microcomplexation AAPS PharmSciTech 14 2013 485 496 23471836 PMC3666019
  85. [93]Hoffman A.S. The early days of PEG and PEGylation (1970s–1990s) Acta Biomater 40 2016 1 5 27221791
  86. [94]Patel K. Doddapaneni R. Sekar V. Chowdhury N. Singh M. Combination approach of YSA peptide anchored docetaxel stealth liposomes with oral antifibrotic agent for the treatment of lung cancer Mol Pharm 13 2016 2049 2058 27070720 PMC5730456
  87. [95]Minato S. Iwanaga K. Kakemi M. Yamashita S. Oku N. Application of polyethyleneglycol (PEG)-modified liposomes for oral vaccine: effect of lipid dose on systemic and mucosal immunity J Control Release 89 2003 189 197 12711443
  88. [96]Daeihamed M. Haeri A. Ostad S.N. Akhlaghi M.F. Dadashzadeh S. Doxorubicin-loaded liposomes: enhancing the oral bioavailability by modulation of physicochemical characteristics Nanomedicine (Lond) 12 2017 1187 1202 28447868
  89. [97]Jain S. Patil S.R. Swarnakar N.K. Agrawal A.K. Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes) Mol Pharm 9 2012 2626 2635 22871060
  90. [98]Jain S. Kumar D. Swarnakar N.K. Thanki K. Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel Biomaterials 33 2012 6758 6768 22748771
  91. [100]Li C. Zhang Y. Su T. Feng L. Long Y. Chen Z. Silica-coated flexible liposomes as a nanohybrid delivery system for enhanced oral bioavailability of curcumin Int J Nanomed 7 2012 5995 6002 PMC3519006 23233804
  92. [101]Mohanraj V.J. Barnes T.J. Prestidge C.A. Silica nanoparticle coated liposomes: a new type of hybrid nanocapsule for proteins Int J Pharm 392 2010 285 293 20363300
  93. [102]Kazakov S. Levon K. Liposome-nanogel structures for future pharmaceutical applications Curr Pharm Des 12 2006 4713 4728 17168774
  94. [103]De Miguel I. Ioualalena K. Bonnefous M. Peyrot M. Nguyen F. Cervilla M. Synthesis and characterization of supramolecular biovector (SMBV) specifically designed for the entrapment of ionic molecules Biochim Biophys Acta 1237 1995 49 58 7619842
  95. [104]von Hoegen P. Synthetic biomimetic supra molecular Biovector™ (SMBV™) particles for nasal vaccine delivery Adv Drug Deliv Rev 51 2001 113 125 11516783
  96. [106]Buck S. Pennefather P.S. Xue H.Y. Grant J. Cheng Y.L. Allen C.J. Engineering lipobeads: properties of the hydrogel core and the lipid bilayer shell Biomacromolecules 5 2004 2230 2237 15530037
  97. [109]Zhang B. Lu Y. Chen J. Wu W. Effects of interior gelation on pharmacokinetics and biodistribution of liposomes encapsulating an anti-cancer drug cytarabine J Biomed Nanotechnol 6 2010 704 709 21361136
  98. [110]Zhang B. Chen J. Lu Y. Qi J. Wu W. Liposomes interiorly thickened with thermosensitive nanogels as novel drug delivery systems Int J Pharm 455 2013 276 284 23872301
  99. [111]Katayama K. Kato Y. Onishi H. Nagai T. Machida Y. Double liposomes: hypoglycemic effects of liposomal insulin on normal rats Drug Dev Ind Pharm 29 2003 725 731 12906329
  100. [114]Thongborisute J. Tsuruta A. Kawabata Y. Takeuchi H. The effect of particle structure of chitosan-coated liposomes and type of chitosan on oral delivery of calcitonin J Drug Target 14 2006 147 154 16753828
  101. [115]Klemetsrud T. Jonassen H. Hiorth M. Kjøniksen A.L. Smistad G. Studies on pectin-coated liposomes and their interaction with mucin Colloids Surf B Biointerfaces 103 2013 158 165 23201733
  102. [116]Han H.K. Shin H.J. Ha D.H. Improved oral bioavailability of alendronate via the mucoadhesive liposomal delivery system Eur J Pharm Sci 46 2012 500 507 22522117
  103. [117]Nguyen S. Alund S.J. Hiorth M. Kjøniksen A.L. Smistad G. Studies on pectin coating of liposomes for drug delivery Colloids Surf B Biointerfaces 88 2011 664 673 21862293
  104. [118]Gradauer K. Vonach C. Leitinger G. Kolb D. Frohlich E. Roblegg E. Chemical coupling of thiolated chitosan to preformed liposomes improves mucoadhesive properties Int J Nanomed 7 2012 2523 2534 PMC3367495 22679365
  105. [119]Werle M. Takeuchi H. Chitosan-aprotinin coated liposomes for oral peptide delivery: development, characterisation and in vivo evaluation Int J Pharm 370 2009 26 32 19073243
  106. [120]Manconi M. Mura S. Manca M.L. Fadda A.M. Dolz M. Hernandez M.J. Chitosomes as drug delivery systems for C-phycocyanin: preparation and characterization Int J Pharm 392 2010 92 100 20338230
  107. [121]Sugihara H. Yamamoto H. Kawashima Y. Takeuchi H. Effectiveness of submicronized chitosan-coated liposomes in oral absorption of indomethacin J Liposome Res 22 2012 72 79 22329417
  108. [122]Takeuchi H. Yamamoto H. Niwa T. Hino T. Kawashima Y. Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes Pharm Res 13 1996 896 901 8792429
  109. [123]Shao Y. Yang L. Han H.K. TPGS-chitosome as an effective oral delivery system for improving the bioavailability of coenzyme Q10 Eur J Pharm Biopharm 89 2015 339 346 25542680
  110. [124]Parmentier J. Hartmann F.J. Fricker G. In vitro evaluation of liposomes containing bio-enhancers for the oral delivery of macromolecules Eur J Pharm Biopharm 76 2010 394 403 20849953
  111. [125]Parmentier J. Hofhaus G. Thomas S. Cuesta L.C. Gropp F. Schröder R. Improved oral bioavailability of human growth hormone by a combination of liposomes containing bio-enhancers and tetraether lipids and omeprazole J Pharm Sci 103 2014 3985 3993 25332052
  112. [127]Degim Z. Ünal N. Eşsiz D. Abbasoglu U. The effect of various liposome formulations on insulin penetration across Caco-2 cell monolayer Life Sci 75 2004 2819 2827 15464833
  113. [128]Chen Y. Lu Y. Chen J. Lai J. Sun J. Hu F. Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt Int J Pharm 376 2009 153 160 19394416
  114. [129]Huang Y.B. Tsai M.J. Wu P.C. Tsai Y.H. Wu Y.H. Fang J.Y. Elastic liposomes as carriers for oral delivery and the brain distribution of (+)-catechin J Drug Target 19 2011 709 718 21303222
  115. [130]Benediktsdóttir B.E. Gudjónsson T. Baldursson Ó. Másson M. N-alkylation of highly quaternized chitosan derivatives affects the paracellular permeation enhancement in bronchial epithelia in vitro Eur J Pharm Biopharm 86 2014 55 63 23608635
  116. [131]Cao J. Sun J. Wang X. Li X. Deng Y. N-trimethyl chitosan-coated multivesicular liposomes for oxymatrine oral delivery Drug Dev Ind Pharm 35 2009 1339 1347 19832634
  117. [132]Huang A. Makhlof A. Ping Q. Tozuka Y. Takeuchi H. N-trimethyl chitosan-modified liposomes as carriers for oral delivery of salmon calcitonin Drug Deliv 18 2011 562 569 21823926
  118. [133]Huang A. Su Z. Li S. Sun M. Xiao Y. Ping Q. Oral absorption enhancement of salmon calcitonin by using both N-trimethyl chitosan chloride and oligoarginines-modified liposomes as the carriers Drug Deliv 21 2014 388 396 24188463
  119. [134]Gradauer K. Barthelmes J. Vonach C. Almer G. Mangge H. Teubl B. Liposomes coated with thiolated chitosan enhance oral peptide delivery to rats J Control Release 172 2013 872 878 24140721 PMC3913890
  120. [135]Zhu Q. Guo T. Xia D. Li X. Zhu C. Li H. Pluronic F127-modified liposome-containing tacrolimus–cyclodextrin inclusion complexes: improved solubility, cellular uptake and intestinal penetration J Pharm Pharmacol 65 2013 1107 1117 23837579
  121. [136]Chen D. Xia D. Li X. Zhu Q. Yu H. Zhu C. Comparative study of Pluronic® F127-modified liposomes and chitosan-modified liposomes for mucus penetration and oral absorption of cyclosporine A in rats Int J Pharm 449 2013 1 9 23583840
  122. [137]Li X. Chen D. Le C. Zhu C. Gan Y. Hovgaard L. Novel mucus-penetrating liposomes as a potential oral drug delivery system: preparation, in vitro characterization, and enhanced cellular uptake Int J Nanomed 6 2011 3151 3162 PMC3235033 22163166
  123. [138]Zhou Y. Ning Q. Yu D.N. Li W.G. Deng J. Improved oral bioavailability of breviscapine via a Pluronic P85-modified liposomal delivery system J Pharm Pharmacol 66 2014 903 911 24697705
  124. [139]Chen H. Torchilin V. Langer R. Lectin-bearing polymerized liposomes as potential oral vaccine carriers Pharm Res 13 1996 1378 1383 8893278
  125. [140]Li K. Chen D. Zhao X. Hu H. Yang C. Pang D. Preparation and investigation of Ulex europaeus agglutinin I-conjugated liposomes as potential oralvaccine carriers Arch Pharm Res 34 2011 1899 1907 22139689
  126. [141]Gupta P.N. Vyas S.P. Investigation of lectinized liposomes as M-cell targeted carrier-adjuvant for mucosal immunization Colloids Surf B Biointerfaces 82 2011 118 125 20843665
  127. [142]Zhang N. Ping Q.N. Huang G.H. Xu W.F. Investigation of lectin-modified insulin liposomes as carriers for oral administration Int J Pharm 294 2005 247 259 15814248
  128. [143]Wang N. Wang T. Zhang M. Chen R. Niu R. Deng Y. Mannose derivative and lipid A dually decorated cationic liposomes as an effective cold chain free oral mucosal vaccine adjuvant-delivery system Eur J Pharm Biopharm 88 2014 194 206 24769065
  129. [144]Wang T. Zhen Y. Ma X. Wei B. Li S. Wang N. Mannosylated and lipid A-incorporating cationic liposomes constituting microneedle arrays as an effective oral mucosal HBV vaccine applicable in the controlled temperature chain Colloids Surf B Biointerfaces 126 2015 520 530 25612819
  130. [145]Zhou F. Kraehenbuhl J.-P. Neutra M.R. Mucosal IgA response to rectally administered antigen formulated in IgA-coated liposomes Vaccine 13 1995 637 644 7668033
  131. [146]Pridgen E.M. Alexis F. Kuo T.T. Levy-Nissenbaum E. Karnik R. Blumberg R.S. Transepithelial transport of Fc-targeted nanoparticles by the neonatal Fc receptor for oral delivery Sci Transl Med 5 2013 213ra167 PMC4023672 24285486
  132. [147]Anderson K.E. Eliot L.A. Stevenson B.R. Rogers J.A. Formulation and evaluation of a folic acid receptor-targeted oral vancomycin liposomal dosage form Pharm Res 18 2001 316 322 11442271
  133. [148]Anderson K.E. Stevenson B.R. Rogers J.A. Folic acid–PEO-labeled liposomes to improve gastrointestinal absorption of encapsulated agents J Control Release 60 1999 189 198 10425325
  134. [149]Zhang X. Qi J. Lu Y. He W. Li X. Wu W. Biotinylated liposomes as potential carriers for the oral delivery of insulin Nanomedicine 10 2014 167 176 23891617
  135. [150]Agrawal A.K. Harde H. Thanki K. Jain S. Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration Biomacromolecules 15 2014 350 360 24283460
  136. [151]Jain S. Harde H. Indulkar A. Agrawal A.K. Improved stability and immunological potential of tetanus toxoid containing surface engineered bilosomes following oral administration Nanomedicine 10 2014 431 440 24036099
  137. [152]des Rieux A. Pourcelle V. Cani P.D. Marchand-Brynaert J. Préat V. Targeted nanoparticles with novel non-peptidic ligands for oral delivery Adv Drug Deliv Rev 65 2013 833 844 23454185
  138. [153]Zhang X. Wu W. Ligand-mediated active targeting for enhanced oral absorption Drug Discov Today 19 2014 898 904 24631680
  139. [154]Patil Y.P. Jadhav S. Novel methods for liposome preparation Chem Phys Lipids 177 2014 8 18 24220497
  140. [155]Shukla D. Chakraborty S. Singh S. Mishra B. Lipid-based oral multiparticulate formulations-advantages, technological advances and industrial applications Exp Opin Drug Deliv 8 2011 207 224 21210754
  141. [158]Pupo E. Padrón A. Santana E. Sotolongo J. Quintana D. Dueñas S. Preparation of plasmid DNA-containing liposomes using a high-pressure homogenization–extrusion technique J Control Release 104 2005 379 396 15907587
  142. [160]Laouini A. Charcosset C. Fessi H. Holdich R. Vladisavljević G. Preparation of liposomes: a novel application of microengineered membranes—from laboratory scale to large scale Colloids Surf B Biointerfaces 112 2013 272 278 23999143
  143. [161]Wagner A. Platzgummer M. Kreismayr G. Quendler H. Stiegler G. Ferko B. Gmp production of liposomes—a new industrial approach J Liposome Res 16 2006 311 319 16952884
  144. [163]Singodia D. Verma A. Khare P. Dube A. Mitra K. Mishra P.R. Investigations on feasibility of in situ development of amphotericin B liposomes for industrial applications J Liposome Res 22 2012 8 17 21682670
  145. [164]Karn P.R. Jin S.-E. Lee B.J. Sun B.K. Kim M.-S. Sung J.H. Preparation and evaluation of cyclosporin A-containing proliposomes: a comparison of the supercritical antisolvent process with the conventional film method Int J Nanomed 9 2014 5079 5091 PMC4224102 25395846
  146. [165]Tantisripreecha C. Jaturanpinyo M. Panyarachun B. Sarisuta N. Development of delayed-release proliposomes tablets for oral protein drug delivery Drug Dev Ind Pharm 38 2012 718 727 21999514
  147. [166]Han M. Watarai S. Kobayashi K. Yasuda T. Application of liposomes for development of oral vaccines: study of in vitro stability of liposomes and antibody response to antigen associated with liposomes after oral immunization J Vet Med Sci 59 1997 1109 1114 9450240
  148. [167]Schubert R. Jaroni H. Schoelmerich J. Schmidt K. Studies on the mechanism of bile salt-induced liposomal membrane damage Digestion 28 1983 181 190 6365666
  149. [168]Werle M. Makhlof A. Takeuchi H. Carbopol-lectin conjugate coated liposomes for oral peptide delivery Chem Pharm Bull 58 2010 432 434 20190459
  150. [169]Niu M. Tan Y. Guan P. Hovgaard L. Lu Y. Qi J. Enhanced oral absorption of insulin-loaded liposomes containing bile salts: a mechanistic study Int J Pharm 460 2014 119 130 24275447
  151. [170]Rescia V.C. Takata C.S. de Araujo P.S. Bueno da Costa M.H. Dressing liposomal particles with chitosan and poly(vinylic alcohol) for oral vaccine delivery J Liposome Res 21 2011 38 45 20470223
  152. [171]Bernkop-Schnürch A. Mucoadhesive systems in oral drug delivery Drug Discov Today Technol 2 2005 83 87 24981759
  153. [173]Wang Y.Y. Lai S.K. Suk J.S. Pace A. Cone R. Hanes J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that “slip” through the human mucus barrier Angew Chem Int Ed Engl 47 2008 9726 9729 18979480 PMC2666733
  154. [174]Yuan H. Chen C.Y. Chai G.H. Du Y.Z. Hu F.Q. Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles Mol Pharm 10 2013 1865 1873 23495754
  155. [176]Thanou M. Verhoef J. Junginger H. Chitosan and its derivatives as intestinal absorption enhancers Adv Drug Deliv Rev 50 2001 S91 S101 11576697
  156. [177]Zambito Y. Zaino C. Di Colo G. Effects of N-trimethylchitosan on transcellular and paracellular transcorneal drug transport Eur J Pharm Biopharm 64 2006 16 25 16527472
  157. [178]Wang J. Li L. Du Y. Sun J. Han X. Luo C. Improved oral absorption of doxorubicin by amphiphilic copolymer of lysine-linked ditocopherol polyethylene glycol 2000 succinate: in vitro characterization and in vivo evaluation Mol Pharm 12 2015 463 473 25581352
  158. [179]Ma Q. Han Y. Chen C. Cao Y. Wang S. Shen W. Oral absorption enhancement of probucol by PEGylated G5 PAMAM dendrimer modified nanoliposomes Mol Pharm 12 2015 665 674 25587935 PMC4770526
  159. [180]Hillaireau H. Couvreur P. Nanocarriers׳ entry into the cell: relevance to drug delivery Cell Mol Life Sci 66 2009 2873 2896 19499185 PMC11115599
  160. [181]Rejman J. Oberle V. Zuhorn I. Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis Biochem J 377 2004 159 169 14505488 PMC1223843
  161. [182]Zhang X. Qi J. Lu Y. Hu X. He W. Wu W. Enhanced hypoglycemic effect of biotin-modified liposomes loading insulin: effect of formulation variables, intracellular trafficking, and cytotoxicity Nanoscale Res Lett 9 2014 1 10 24739082 PMC3996857
  162. [183]Jain S. Indulkar A. Harde H. Agrawal A.K. Oral mucosal immunization using glucomannosylated bilosomes J Biomed Nanotechnol 10 2014 932 947 24749389
  163. [184]des Rieux A. Fievez V. Garinot M. Schneider Y.-J. Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach J Control Release 116 2006 1 27 17050027
  164. [186]Ling S.S. Magosso E. Khan N.A. Yuen K.H. Barker S.A. Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes Drug Dev Ind Pharm 32 2006 335 345 16556538
  165. [187]Tomizawa H. Aramaki Y. Fujii Y. Kara T. Suzuki N. Yachi K. Uptake of phosphatidylserine liposomes by rat Peyer׳s patches following intraluminal administration Pharm Res 10 1993 549 552 8483837
  166. [188]Aramaki Y. Tomizawa H. Hara T. Yachi K. Kikuchi H. Tsuchiya S. Stability of liposomes in vitro and their uptake by rat Peyer׳s patches following oral administration Pharm Res 10 1993 1228 1231 8415412
  167. [189]Rogers J.A. Anderson K.E. The potential of liposomes in oral drug delivery Crit Rev Ther Drug Carr Syst 15 1998 421 480 9822867
  168. [190]Channarong S. Chaicumpa W. Sinchaipanid N. Mitrevej A. Development and evaluation of chitosan-coated liposomes for oral DNA vaccine: the improvement of Peyer׳s patch targeting using a polyplex-loaded liposomes AAPS PharmSciTech 12 2011 192 200 21194014 PMC3066342

Cited by

Sorted by citations

Authors
He, H., Lu, Y., Qi, J., Zhu, Q., Chen, Z., & Wu, W.
Affiliations
Fudan University (CN)
Corresponding author
  • Chen, Zhongjian
  • Wu, Wei
ORCID
Venue
Acta Pharmaceutica Sinica B
Publisher
Elsevier BV
Published
2019-01
Volume
9
Issue
1
Pages
36-48
ISSN
2211-3835 (ISSN-L)
DOI
10.1016/j.apsb.2018.06.005
PMC
PMC6362257
OpenAlex
W2809183137
Cited by
663
References
4
Citations by year
2026: 47 · 2025: 103 · 2024: 109 · 2023: 99 · 2022: 101 · 2021: 84 · 2020: 79 · 2019: 36 · 2018: 5
FWCI
4.46
Type
journal article
Language
en
Open access
Licence
Locations
  • Acta Pharmaceutica Sinica B (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81573363, 81690263)
  • National Key Basic Research Program (2015CB931800)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
liposomes, oral drug delivery, lipid bilayer composition, gastrointestinal stability, membrane permeability, polymers, ligands, drug carriers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review